NasdaqGS:IMVTBiotechs
Can Immunovant's (IMVT) New Data on Batoclimab Reveal a Path to Durable Innovation?
Immunovant announced six-month off-treatment data from a proof-of-concept study evaluating batoclimab in patients with active Graves' disease, which will be presented at the 2025 Annual Meeting of the American Thyroid Association on September 11.
This long-term data highlights potential for batoclimab to manage thyroid hormone levels beyond the treatment period, indicating important clinical progress for the company.
We'll explore how this newly released six-month follow-up data shapes...